HBPE-DFO[CT20p] (Cedars-Sinai Medical Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHBPE-DFO[CT20p] (Cedars-Sinai Medical Center)
Drug Alias NameCT20pHBPE-DFO[CT20p] (University of Central Florida)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Central Florida
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of Central FloridaCedars-Sinai Medical Center
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A